DOCSLIB.ORG

Us 2019 / 0160078 A1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Us 2019 / 0160078 A1 US 20190160078A1 ( 19) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0160078 A1 Masuoka et al. ( 43 ) Pub . Date: May 30 , 2019 ( 54 ) GANAXOLONE FOR USE IN TREATING A61K 47 / 38 (2006 .01 ) GENETIC EPILEPTIC DISORDERS A61K 47 34 ( 2006 .01 ) A61K 47 / 24 (2006 .01 ) ( 71 ) Applicant: Marinus Pharmaceuticals , Inc ., A61K 47 / 12 ( 2006 .01 ) Radnor, PA (US ) A61K 47 /26 ( 2006 . 01 ) A61P 25 / 08 (2006 . 01) ( 72 ) Inventors : Lorianne K . Masuoka , Chestnut Hill, (52 ) U . S . CI. MA (US ) ; Jaakko Lappalainen , CPC . A61K 31 /565 ( 2013 .01 ) ; A61K 9 /08 Wilmington , DE (US ) ( 2013 . 01 ) ; A61K 9 /4866 ( 2013 .01 ) ; A61K 9 /4858 (2013 .01 ) ; A61K 9 /485 ( 2013 .01 ) ; (73 ) Assignee : Marinus Pharmaceuticals , Inc . , A61P 25 / 08 (2018 .01 ) ; A61K 47 /34 ( 2013 .01 ) ; Radnor, PA (US ) A61K 47 /24 ( 2013 .01 ) ; A61K 47/ 12 ( 2013 .01 ) ; ( 21 ) Appl. No. : 16 /185 ,677 A61K 47 / 26 ( 2013 .01 ) ; A61K 47 / 38 ( 2013 .01 ) ( 22 ) Filed : Nov . 9 , 2018 (57 ) ABSTRACT Related U . S . Application Data The disclosure provides a method of treating a mammal having a genetic epileptic disorder , comprising chronically (60 ) Provisional application No . 62 /584 ,403 , filed on Nov. administering a pharmaceutically acceptable pregnenolone 10 , 2017 . neurosteroid to a mammal having a genetic epileptic disor der in an amount effective to reduce the seizure frequency in Publication Classification the mammal. In certain preferred embodiments , the mammal (51 ) Int . Cl. is a human patient who has a CDKL5 genetic mutation . In A61K 31/ 565 ( 2006 . 01 ) certain preferred embodiments, the patient has a low endog A61K 9 /08 ( 2006 .01 ) enous level of a neurosteroid ( s ) . In certain preferred embodi A61K 9 / 48 ( 2006 . 01 ) ments , the pregnenolone neurosteroid is ganaxolone . Patent Application Publication May 30 , 2019 Sheet 1 of 11 US 2019 /0160078 A1 Figure 1 . Figure 2 . Horios 14960 VS VA930 USO Particis Size . : . .: . Sinin : . iiiii . : .: . sinisis . : . : . : . : . : . : . : . : . : . : . :. : . .? .1 Patent Application Publication May 30 , 2019 Sheet 2 of 11 US 2019 /0160078 A1 Figure 3A Milling Slurry MAA 25 % ganaxolone Milling Dispersion 25 % ganaxolone Diluted Dispersion 20 % ganaxolone Stabilized Dispersion 19 . 9 % ganaxolone Intermediate Suspension Dilution Coating Feed Dispersion 8 % ganaxolone 10 . 9 % ganaxolone Final Suspension Dilution IR Coated Bead 4 . 9 % ganaxolone 45 % ganaxolone Filling & Bottling Encapsulation 225 mg capsule WA 50 mg/ ml Suspension Patent Application Publication May 30 , 2019 Sheet 3 of 11 US 2019 /0160078 A1 Figure 3B Vessel mixing of ganaxolone in aqueous stabilizer solution to form ganaxolone slurry Recirculation of ganaxolone slurry through NanoMill to reduce particle size of Milled Dispersion to approx . 150 nm Dilution ofMilled Dispersion Addition of stabilizing agents to stabilize particle size at approx. 300 nm Initial dilution of suspension to approx . 8 % ganaxolone Final dilution of suspension to 50 mg /ml Drug product packaging Patent Application Publication May 30 , 2019 Sheet 4 of 11 US 2019 /0160078 A1 Figure 3C Vessel mixing of ganaxolone in aqueous stabilizer solution to form ganaxolone slurry Recirculation of ganaxolone slurry through NanoMill to reduce particle size of Milled Dispersion to approx. 150 nm Dilution of Milled Dispersion Addition of stabilizing agents to stabilize particle size at vo approx . 300 nm Addition of coating excipients to form ganaxolone Coating Feed Dispersion Vio Fluid Bed Coating of ganaxolone Coating Feed Dispersion onto microcrystalline cellulose spheres to form Immediate W Release (IR ) Beads Encapsulation of ganaxolone immediate Release Beads into hard gelatin capsules Patent Application Publication May 30 , 2019 Sheet 5 of 11 US 2019 /0160078 A1 Figure 3D Particle Size Stability of Ganaxolone Nanomilled Suspension .. batch 16M - 144 bulk IR beads. batch 161M - 221, and encapsulated IR beads ( 161M - 345 ) , Horiba LA - 910 vs . LA - 960 , 703 . crrrrrrr . rrrrrrrrrr . (d50 . ,.mean . .. n = 3 ) . crrrrrrrrrrrrrrrrrrrrrrrrrrrr -* 2 W Figure 3B Curing Curve of Ganaxolone Particles Containing Parabens D50(nm) No sonication 1 min sonication 10 3040 Time (days ) Patent Application Publication May 30 , 2019 Sheet 6 of 11 US 2019 /0160078 A1 Figure 4 PC H19 ( N - } } } .. .. .. .. - 13 .. .. .. 3 - m o genown Patent Application Publication May 30 , 2019 Sheet 7 of 11 US 2019 /0160078 A1 Figure 5 . , , , , , , , , , , , , , , , , , , , , , , , . Figure 6 300 . -.- GanakoloneConcentrtion(nom.) . - * . * Patent Application Publication May 30 , 2019 Sheet 8 of 11 US 2019 /0160078 A1 Figure 7 . 009 . Ganaxoloneconcentrtion(ngml.) . - . - . - . 4. - . - . 2 . 1 . Figure 8 - 009 NSW= OC Concentration(namL) Patent Application Publication May 30 , 2019 Sheet 9 of 11 US 2019 /0160078 A1 Figure 9 1000 100 Concentration(ng/mL) 1111111 0 2 4 6 8 10 12 14 16 18 Time (Day ) Figure 10 15, 000 10 .000 Responders Non -responders Patent Application Publication May 30 , 2019 Sheet 10 of 11 US 2019 /0160078 A1 Figure 11 20 , 000 Non - responder 15 , 000 10 , 000 [A110-9),pgmL 5 , 000 i m rker biomarker . 1 - 100 - 50 00 00 5 15 % A seizure frequency 1000 Figure 12 500 300 1.1460) plasmaAllopregnanolone 200 1 0 0 - 100 - 50 50 100 150 % A se izure frequency Patent Application Publication May 30 , 2019 Sheet 11 of 11 US 2019 /0160078 A1 Figure 13 50007 . Study 1042- 0403 ( 0 . 3 -x capsule ) Study 1042- 0404 ( 0 . 3 - 1 capsule ) 40001 AUC-2455)(ng*himL 800 1200 1600 Dose mg( / day ) US 2019 /0160078 A1 May 30 , 2019 GANAXOLONE FOR USE IN TREATING peutic agents ( e . g . , anticonvulsants ) are used together to GENETIC EPILEPTIC DISORDERS treat PCDH19 - related epilepsy, Dravet Syndrome, Lennox Gastaut syndrome (LGS ) , Continuous Sleep Wave in Sleep CROSS - REFERENCE TO RELATED (CSWS ) , Epileptic Status Epilepticus in Sleep (ESES ) , and APPLICATION other intractable epilepsy conditions and refractory genetic epilepsy conditions that clinically resemble PCDH19 - re [ 0001 ] This application claims priority from U . S . Provi lated epilepsy , CDKL5 Deficiency Disorder, Dravet Syn sional Application No . 62/ 584 , 403 , filed on Nov. 10 , 2017 , drome, LGS , CSWS , and ESES . the disclosure of which is hereby incorporated by reference [0007 ] There are also no approved or licensed therapies in in its entirety for all purposes. the United States for the treatment of patients with CDKL5 deficiency disorder . There is also no accepted standard of BACKGROUND OF THE INVENTION care , nor are there guidelines from authoritative scientific [ 0002 ] Infantile epileptic encephalopathies and rare pedi bodies regarding the treatment of these patients . However, atric epilepsies are conditions of significant unmet medical most antiepileptic drugs (“ AEDs” ) , including steroids /adre need . These conditions include PCDH19 - related epilepsy , nocorticotropic hormone (ACTH ) , ketogenic diet, vagal CDKL5 Deficiency Disorder ( CDD ) , Dravet Syndrome, nerve stimulation , and corpus callosotomy (to disrupt inter Lennox -Gastaut syndrome (LGS ) , Continuous Sleep Wave hemispheric connections for reduction of secondarily gen in Sleep (CSWS ) , Epileptic Status Epilepticus in Sleep eralized seizures) have been tried to treat this condition . ( ESES ), and other intractable and refractory genetic epilepsy [0008 ] Efficacy of multiple AEDs and ketogenic diet in conditions that clinically resemble PCDH19 - related epi patients with the CDKL5 mutation is very low . Newer drugs lepsy , CDKL5 Deficiency Disorder , Dravet Syndrome, LGS, tend to be less sedating , have fewer adverse effects on CSWS , and ESES . memory and learning , and are less likely to cause allergic [0003 ] PCDH19 - related epilepsy is a serious and rare reactions and serious side effects. However , some of the epileptic syndrome that predominantly affects females . The most commonly used AEDs to treat CDKL5 deficiency condition is caused by an inherited mutation of the proto disorder - associated seizures are associated with the follow cadherin 19 (PCDH19 ) gene , located on the X chromosome, ing severe adverse effects : and is characterized by early -onset and highly variable [ 0009 ] Cognitive side effects are a considerable concern cluster seizures, cognitive and sensory impairment, and with topiramate . behavioral disturbances . Currently , there are no approved [0010 ) Felbamate can cause aplastic anemia or liver therapies for PCDH19 -related epilepsy , nor is there any failure . effective standard of care therapy . [ 0011 ] Vigabatrin can permanently reduce a child ' s [0004 ] CDKL5 is a rare X linked genetic disorder that results in early onset, difficult to control seizures, and severe field of vision . neuro -developmental impairment. The most common fea [0012 ] Stevens - Johnson syndrome, a severe allergic ture of CDKL5 deficiency disorder is early drug - resistant drug reaction , remains a concern with lamotrigine. epilepsy, usually starting in the firstmonths of life . Seizures [ 0013 ] Compared to the pre - 1990 drugs , many of the are generally highly polymorphic . Complex partial seizures, newer drugs have a broader range of action , making them infantile spasms, myoclonic , generalized tonic - clonic , and more likely to work for generalized seizures . However, tonic seizures have all been reported . Many different seizure some , like gabapentin , pregabalin , oxcarbazepine , and types can also occur in the same patient, changing with time tiagabine, seem to
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Caractérisation De La Polarisation Des Macrophages Pulmonaires Humains Et Voies De Régulation Charlotte Abrial
    Caractérisation de la polarisation des macrophages pulmonaires humains et voies de régulation Charlotte Abrial To cite this version: Charlotte Abrial. Caractérisation de la polarisation des macrophages pulmonaires humains et voies de régulation. Biologie cellulaire. Université de Versailles-Saint Quentin en Yvelines, 2014. Français. NNT : 2014VERS0033. tel-01326578 HAL Id: tel-01326578 https://tel.archives-ouvertes.fr/tel-01326578 Submitted on 8 Dec 2016 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Université de Versailles Saint Quentin en Yvelines UFR DES SCIENCES DE LA SANTÉ École doctorale GAO "Des génomes aux organismes" Année universitaire 2014 – 2015 N° le 03 novembre 2014 THESE DE DOCTORAT Présentée pour l’obtention du grade de DOCTEUR DE L’UNIVERSITÉ VERSAILLES – SAINT QUENTIN EN YVELINES Spécialité : Biologie cellulaire Par Charlotte ABRIAL Caractérisation de la polarisation des macrophages pulmonaires humains et voies de régulation Composition du jury: Directeur de thèse Pr. DEVILLIER Philippe Rapporteur Dr. FROSSARD Nelly Rapporteur Pr. LAGENTE Vincent Examinateur Dr. TOUQUI Lhousseine Université de Versailles Saint Quentin en Yvelines UFR DES SCIENCES DE LA SANTÉ École doctorale GAO "Des génomes aux organismes" Année universitaire 2014 – 2015 N° THESE DE DOCTORAT Présentée pour l’obtention du grade de DOCTEUR DE L’UNIVERSITÉ VERSAILLES – SAINT QUENTIN EN YVELINES Spécialité : Biologie cellulaire Par Charlotte ABRIAL Caractérisation de la polarisation des macrophages pulmonaires humains et voies de régulation Composition du jury: Directeur de thèse Pr.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • 1-(4-Amino-Cyclohexyl)
    (19) & (11) EP 1 598 339 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 211/04 (2006.01) C07D 211/06 (2006.01) 24.06.2009 Bulletin 2009/26 C07D 235/24 (2006.01) C07D 413/04 (2006.01) C07D 235/26 (2006.01) C07D 401/04 (2006.01) (2006.01) (2006.01) (21) Application number: 05014116.7 C07D 401/06 C07D 403/04 C07D 403/06 (2006.01) A61K 31/44 (2006.01) A61K 31/48 (2006.01) A61K 31/415 (2006.01) (22) Date of filing: 18.04.2002 A61K 31/445 (2006.01) A61P 25/04 (2006.01) (54) 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ON DERIVATE UND VERWANDTE VERBINDUNGEN ALS NOCICEPTIN ANALOGE UND ORL1 LIGANDEN ZUR BEHANDLUNG VON SCHMERZ DERIVÉS DE LA 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE ET COMPOSÉS SIMILAIRES POUR L’UTILISATION COMME ANALOGUES DU NOCICEPTIN ET LIGANDES DU ORL1 POUR LE TRAITEMENT DE LA DOULEUR (84) Designated Contracting States: • Victory, Sam AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Oak Ridge, NC 27310 (US) MC NL PT SE TR • Whitehead, John Designated Extension States: Newtown, PA 18940 (US) AL LT LV MK RO SI (74) Representative: Maiwald, Walter (30) Priority: 18.04.2001 US 284666 P Maiwald Patentanwalts GmbH 18.04.2001 US 284667 P Elisenhof 18.04.2001 US 284668 P Elisenstrasse 3 18.04.2001 US 284669 P 80335 München (DE) (43) Date of publication of application: (56) References cited: 23.11.2005 Bulletin 2005/47 EP-A- 0 636 614 EP-A- 0 990 653 EP-A- 1 142 587 WO-A-00/06545 (62) Document number(s) of the earlier application(s) in WO-A-00/08013 WO-A-01/05770 accordance with Art.
    [Show full text]
  • Clonazepam/Ethosuximide 479 Abnormal Movements, and for the Treatment of Panic BNFC Suggests Giving the Following Doses by Slow Intravenous 3
    Clonazepam/Ethosuximide 479 abnormal movements, and for the treatment of panic BNFC suggests giving the following doses by slow intravenous 3. Peled R, Lavie P. Double-blind evaluation of clonazepam on pe- injection over at least 2 minutes according to age: riodic leg movements in sleep. J Neurol Neurosurg Psychiatry disorder (see Psychiatric Disorders, below). 1987; 50: 1679–81. For epilepsy and myoclonus treatment is started with • neonates: 100 micrograms/kg, repeated if necessary after 24 4. Saletu M, et al. Restless legs syndrome (RLS) and periodic limb hours movement disorder (PLMD): acute placebo-controlled sleep lab- small doses that are progressively increased to an opti- oratory studies with clonazepam. Eur Neuropsychopharmacol • 1 month to 12 years: 50 micrograms/kg (maximum 1 mg), re- 2001; 11: 153–61. mum dose according to response. Total daily doses peated if necessary may initially be taken in 3 or 4 divided doses; however, 5. Saletu A, et al. On the pharmacotherapy of sleep bruxism: place- Older children may be given the usual adult dose. bo-controlled polysomnographic and psychometric studies with once the maintenance dose has been reached, the daily clonazepam. Neuropsychobiology 2005; 51: 214–25. In children aged over 1 month, these doses by injection may be amount may be given as a single dose at night. In the followed by an intravenous infusion of 10 micrograms/kg per Stiff-man syndrome. Clonazepam has been used as an alter- UK the initial oral dose is 1 mg (500 micrograms in the native to diazepam in the management of stiff-man syndrome hour, adjusted according to response to a maximum of 1 elderly) at night for 4 nights gradually increased over 2 60 micrograms/kg per hour.
    [Show full text]
  • Mechanisms of Action of Antiepileptic Drugs
    Review Mechanisms of action of antiepileptic drugs Epilepsy affects up to 1% of the general population and causes substantial disability. The management of seizures in patients with epilepsy relies heavily on antiepileptic drugs (AEDs). Phenobarbital, phenytoin, carbamazepine and valproic acid have been the primary medications used to treat epilepsy for several decades. Since 1993 several AEDs have been approved by the US FDA for use in epilepsy. The choice of the AED is based primarily on the seizure type, spectrum of clinical activity, side effect profile and patient characteristics such as age, comorbidities and concurrent medical treatments. Those AEDs with broad- spectrum activity are often found to exert an action at more than one molecular target. This article will review the proposed mechanisms of action of marketed AEDs in the US and discuss the future of AEDs in development. 1 KEYWORDS: AEDs anticonvulsant drugs antiepileptic drugs epilepsy Aaron M Cook mechanism of action seizures & Meriem K Bensalem-Owen† The therapeutic armamentarium for the treat- patients with refractory seizures. The aim of this 1UK HealthCare, 800 Rose St. H-109, ment of seizures has broadened significantly article is to discuss the past, present and future of Lexington, KY 40536-0293, USA †Author for correspondence: over the past decade [1]. Many of the newer AED pharmacology and mechanisms of action. College of Medicine, Department of anti epileptic drugs (AEDs) have clinical advan- Neurology, University of Kentucky, 800 Rose Street, Room L-455, tages over older, so-called ‘first-generation’ First-generation AEDs Lexington, KY 40536, USA AEDs in that they are more predictable in their Broadly, the mechanisms of action of AEDs can Tel.: +1 859 323 0229 Fax: +1 859 323 5943 dose–response profile and typically are associ- be categorized by their effects on the neuronal [email protected] ated with less drug–drug interactions.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/014.3507 A1 Gant Et Al
    US 2010.0143507A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/014.3507 A1 Gant et al. (43) Pub. Date: Jun. 10, 2010 (54) CARBOXYLIC ACID INHIBITORS OF Publication Classification HISTONE DEACETYLASE, GABA (51) Int. Cl. TRANSAMINASE AND SODIUM CHANNEL A633/00 (2006.01) A 6LX 3/553 (2006.01) A 6LX 3/553 (2006.01) (75) Inventors: Thomas G. Gant, Carlsbad, CA A63L/352 (2006.01) (US); Sepehr Sarshar, Cardiff by A6II 3/19 (2006.01) the Sea, CA (US) C07C 53/128 (2006.01) A6IP 25/06 (2006.01) A6IP 25/08 (2006.01) Correspondence Address: A6IP 25/18 (2006.01) GLOBAL PATENT GROUP - APX (52) U.S. Cl. .................... 424/722:514/211.13: 514/221; 10411 Clayton Road, Suite 304 514/456; 514/557; 562/512 ST. LOUIS, MO 63131 (US) (57) ABSTRACT Assignee: AUSPEX The present invention relates to new carboxylic acid inhibi (73) tors of histone deacetylase, GABA transaminase, and/or PHARMACEUTICALS, INC., Sodium channel activity, pharmaceutical compositions Vista, CA (US) thereof, and methods of use thereof. (21) Appl. No.: 12/632,507 Formula I (22) Filed: Dec. 7, 2009 Related U.S. Application Data (60) Provisional application No. 61/121,024, filed on Dec. 9, 2008. US 2010/014.3507 A1 Jun. 10, 2010 CARBOXYLIC ACID INHIBITORS OF HISTONE DEACETYLASE, GABA TRANSAMNASE AND SODIUM CHANNEL 0001. This application claims the benefit of priority of Valproic acid U.S. provisional application No. 61/121,024, filed Dec. 9, 2008, the disclosure of which is hereby incorporated by ref 0004 Valproic acid is extensively metabolised via erence as if written herein in its entirety.
    [Show full text]
  • Deutsche Gesellschaft Für Experimentelle Und Klinische Pharmakologie Und Toxikologie E.V
    Naunyn-Schmiedeberg´s Arch Pharmacol (2013 ) 386 (Suppl 1):S1–S104 D OI 10.1007/s00210-013-0832-9 Deutsche Gesellschaft für Experimentelle und Klinische Pharmakologie und Toxikologie e.V. Abstracts of the 79 th Annual Meeting March 5 – 7, 2013 Halle/Saale, Germany This supplement was not sponsored by outside commercial interests. It was funded entirely by the publisher. 123 S2 S3 001 003 Multitarget approach in the treatment of gastroesophagel reflux disease – Nucleoside Diphosphate Kinase B is a Novel Receptor-independent Activator of comparison of a proton-pump inhibitor with STW 5 G-protein Signaling in Clinical and Experimental Atrial Fibrillation Abdel-Aziz H.1,2, Khayyal M. T.3, Kelber O.2, Weiser D.2, Ulrich-Merzenich G.4 Abu-Taha I.1, Voigt N.1, Nattel S.2, Wieland T.3, Dobrev D.1 1Inst. of Pharmaceutical & Medicinal Chemistry, University of Münster Pharmacology, 1Universität Duisburg-Essen Institut für Pharmakologie, Hufelandstr. 55, 45122 Essen, Hittorfstr 58-62, 48149 Münster, Germany Germany 2Steigerwald Arzneimittelwerk Wissenschaft, Havelstr 5, 64295 Darmstadt, Germany 2McGill University Montreal Heart Institute, 3655 Promenade Sir-William-Osler, Montréal 3Faculty of Pharmacy, Cairo University Pharmacology, Cairo Egypt Québec H3G 1Y6, Canada 4Medizinische Poliklinik, University of Bonn, Wilhelmstr. 35-37, 53111 Bonn, Germany 3Medizinische Fakultät Mannheim der Universität Heidelberg Institutes für Experimentelle und Klinische Pharmakologie und Toxikologie, Maybachstr. 14, 68169 Gastroesophageal reflux disease (GERD) was the most common GI-diagnosis (8.9 Mannheim, Germany million visits) in the US in 2012 (1). Proton pump inhibitors (PPI) are presently the mainstay of therapy, but in up to 40% of the patients complete symptom control fails.
    [Show full text]
  • 8Th European Congress on Epileptology, Berlin, Germany, 21 – 25 September 2008
    Epilepsia, 50(Suppl. 4): 2–262, 2009 doi: 10.1111/j.1528-1167.2009.02063.x 8th ECE PROCEEDINGS 8th European Congress on Epileptology, Berlin, Germany, 21 – 25 September 2008 Sunday 21 September 2008 KV7 channels (KV7.1-5) are encoded by five genes (KCNQ1-5). They have been identified in the last 10–15 years by discovering the caus- 14:30 – 16:00 ative genes for three autosomal dominant diseases: cardiac arrhythmia Hall 1 (long QT syndrome, KCNQ1), congenital deafness (KCNQ1 and KCNQ4), benign familial neonatal seizures (BFNS, KCNQ2 and VALEANT PHARMACEUTICALS SATELLITE SYM- KCNQ3), and peripheral nerve hyperexcitability (PNH, KCNQ2). The fifth member of this gene family (KCNQ5) is not affected in a disease so POSIUM – NEURON-SPECIFIC M-CURRENT K+ CHAN- far. The phenotypic spectrum associated with KCNQ2 mutations is prob- NELS: A NEW TARGET IN MANAGING EPILEPSY ably broader than initially thought (i.e. not only BFNS), as patients with E. Perucca severe epilepsies and developmental delay, or with Rolando epilepsy University of Pavia, Italy have been described. With regard to the underlying molecular pathophys- iology, it has been shown that mutations in KCNQ2 and KCNQ3 Innovations in protein biology, coupled with genetic manipulations, have decrease the resulting K+ current thereby explaining the occurrence of defined the structure and function of many of the voltage- and ligand- epileptic seizures by membrane depolarization and increased neuronal gated ion channels, channel subunits, and receptors that are the underpin- firing. Very subtle changes restricted to subthreshold voltages are suffi- nings of neuronal hyperexcitability and epilepsy. Of the currently cient to cause BFNS which proves in a human disease model that this is available antiepileptic drugs (AEDs), no two act in the same way, but all the relevant voltage range for these channels to modulate the firing rate.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Ganaxolone (Epilepsy) – Forecast and Market Analysis to 2022
    Ganaxolone (Epilepsy) – Forecast and Market Analysis to 2022 Reference Code: GDHC1071DFR Publication Date: February 2013 Executive Summary Epilepsy: Key Metrics in the Epilepsy Markets The below figure illustrates ganaxolone sales for the US 2022 Market Sales and 5EU during the forecast period. US $43.17m Sales for Ganaxolone by Region, 2022 5EU $4.64m Total $47.81m 10% 2012 Total: $47.81m Key Events (2012–2022) Level of Impact Launch of ganaxolone in the US in 2019 ↑↑↑ US Launch of ganaxolone in the 5EU in 2019 ↑↑↑ 5EU Source: GlobalData Sales for Ganaxolone in the Epilepsy Market GlobalData expects Marinus Pharmaceuticals to launch 90% ganaxolone in the US and EU in 2019. We estimate that 2022 sales of ganaxolone will reach $47.81m across Source: GlobalData these markets. Key factors affecting the uptake of ganaxolone will include: What Do the Physicians Think? Novel mechanism of action and good tolerability Overall physicians expressed a need for more AEDs profile and favorable opinions of those in pipeline Efficacy profile is not significantly different from that development. of other marketed anti-epileptic drugs (AEDs) “Among intractable epilepsy patients, any drug that helps Ganaxolone is still in early development; possible treat an additional segment of them will be used, and lack of funding to conduct Phase III trials necessary because we don’t have a basis for using one or another, for commercialization if it’s attractive, it will be used more.” [US] key opinion leader, November 2012 Heavy competition in the market “Brivaracetam is an interesting concept because it’s supposed to be “Super Keppra,” the follow-on from Keppra.
    [Show full text]